Total Funding
67
66
Total FundingSeries D raised
Growth Score 67 in past quarter
-7 pts
Heat Score 66 in past quarter
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
8226
EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.
- Kenneth Fan: Chief Operating Officer
- William Westlin: Executive Vice President of Research and DevelopmentPast Role: Nimbus Therapeutics, Vice President, Preclinical Research & Early Development
About the Company
EGenesis is a biotechnology company developing solid organ and therapeutic cell transplantation to treat diseases. It offers gene editing and genome engineering platform to develop human-compatible organs, tissues, and cells, aiming to provide an alternative solution to the global organ shortage.
Women Founded